Tomlins et al. combined the detection of TMPRSS2:ERG fusion transcripts and PCA3 with serum PSA levels and the result from the multivariate Prostate Cancer Prevention Trial risk calculator version 1.0 (PCPT-RC) in a combined predictor, which they called Mi-Prostate score (MiPS) [61]. This evidence concerns the gene PCA3 and Familial prostate cancer.